Description
Product Overview
CJC-1295 Without DAC is the catalogue name commonly used for Modified GRF (1-29), a modified GHRH analogue supplied for controlled laboratory research.
Unlike the DAC-containing formulation, this research peptide does not incorporate the albumin-binding Drug Affinity Complex used to extend peptide persistence. This makes the no-DAC material particularly relevant to studies examining shorter-duration GHRH-related signalling and temporal receptor activity.
Pronoia supplies CJC-1295 Without DAC as a 5mg lyophilised research material with batch traceability and supporting documentation available.
Product Specification
Product: CJC-1295 Without DAC
Alternative name: Modified GRF (1-29)
Specification: 5mg
Material class: Modified GHRH analogue
DAC modification: Not present
Form: Lyophilised solid
Minimum purity standard: ≥98%
Batch traceability: Maintained
SKU: PB-CJC-5
Quality, Testing & Traceability
Pronoia maintains batch traceability for CJC-1295 Without DAC and retains supporting analytical documentation for the supplied research material.
Independent analytical testing supports product quality assessment, with batch-specific documentation used to record identity, purity and consistency.
Where a particular analytical method or result is reported for an individual batch, the corresponding Certificate of Analysis should be treated as the authoritative reference.
Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation are available to support laboratory records and material assessment.
Research Context
Modified GRF (1-29) belongs to a class of peptides investigated in research examining growth hormone-releasing hormone signalling and receptor interactions.
Relevant experimental areas include:
- GHRH-receptor signalling mechanisms
- Temporal peptide signalling dynamics
- Endocrine signalling models
- Peptide–receptor interaction studies
- Structure–function relationships of modified GHRH analogues
- Comparison of shorter- and extended-duration peptide designs
The absence of the DAC modification provides a useful contrast with albumin-binding GHRH analogues, allowing researchers to investigate how structural modification can influence peptide persistence and signalling behaviour.
These contexts describe laboratory research applications only and do not imply suitability for human or veterinary use.
Storage & Handling
CJC-1295 Without DAC is supplied in lyophilised form to support stability during storage and laboratory handling.
The product should be maintained under the temperature-controlled conditions specified by Pronoia and the applicable batch documentation, protected from unnecessary heat, moisture and repeated environmental exposure.
Researchers should follow appropriate laboratory procedures when preparing or handling the material and use validated protocols appropriate to their individual experimental requirements.
Where batch-specific storage instructions are supplied, those instructions should take precedence.
Delivery & Documentation
CJC-1295 Without DAC is supplied through Pronoia’s tracked UK delivery service using its established research-product fulfilment process.
Batch traceability is maintained, with Certificate of Analysis (COA) and Safety Data Sheet (SDS) documentation available to support laboratory records and material assessment.
Current dispatch availability and applicable delivery conditions are displayed directly on the product page and remain subject to Pronoia’s delivery terms.
Research Use Statement
CJC-1295 Without DAC supplied by Pronoia Bio is intended strictly for controlled laboratory research and experimental use.
It is not supplied for human or veterinary use and should not be treated as a medicine or consumer healthcare product.
Purchasers are responsible for ensuring that the material is used appropriately within their research environment and in accordance with applicable requirements.
